2-methyl-5-androst-16-en-3-one as an olfactory stimulant reproductive functions of female pigs and cows

 

(57) Abstract:

The invention relates to the field of chemistry artificial navigability sex pheromone analogues of 5-androst-16-EN-3-one, namely, 2-methyl-5-androst-16-EN-3-ONU formula I, which can be used on livestock farms, including industrial, as stimulants reproductive function of females.

The invention relates to the field of chemistry artificial navigability sex pheromone analogues of 5-androst-16-EN-3-one, which can be used on livestock farms, including industrial, as stimulants reproductive function of females.

Known of the natural sex pheromone of the boar 5-androst-16-EN-3-one and some of its analogues [1, 2, 3]. A disadvantage of the known natural boar pheromone, which is used for pigs and cows, is relatively large single effective dose is about 50 mg.

The aim of the present invention is the creation of new natural sex pheromone with a higher efficiency.

The task is solved by the synthesis of 2-methylpropanol 5-androst-16-EN-3-one, which serves as an olfactory stimulant bezvestnogo equivalent.

Obtaining 2-methyl-5-androst - 16-EN-3-one.

Example 1. A solution of 56 mg of potassium in 2.6 ml of tert-butanol dobyavlyayut to the boiling solution of 281 mg of 5-androst-16-EN-3-one in a mixture of 3.2 ml of benzene and 1.3 ml of tert-butanol, then rapidly added to 0.8 ml of a mixture of benzene-methyl iodide 1: 1, boiled for 3 min, diluted with water (5 ml), extracted with ether (2x10 ml), the extract is dried Na2SO4, evaporated and the target reaction product methylation allocate individual using preparative VSGH (column Liposorb S160 22,4 x 250 mm, hexanitrate of 98.2, 20 ml/min). Mass spectrum (M/z, intensity in % of the maximum peak): 286 (100, M ), 271 (97, M- 15), 253 (12), 187 (15), 149 (68), 91 (60). PMR-spectrum (M. D.): 0,79 (3H, s), 1,1 (3H, d, J=6 Hz), 1,11 (3H, s), 2,47 (1H, m), 2,34 (2H, m), 5,70 (1H, m), of 5.84 (1H, m).

The use of the proposed artificial pheromone and its infusion on the parameters of reproduction of farm animals

Example 2. Treatment of pigs with a water-alcohol solution of the proposed pheromone (0.1 ág/ml) in the amount of 0.1 ml per head (single dose) 1) accelerates joining a hunt pigs for 5 days; 2) increases fertility by 10%; 3) increase the prolificacy of 0.5 piglets per litter.

Example 3. Treatment of nasal mirror cows held 1 time in succ processing - 8 nights. 1) improving the fertility of cows by 20%, 2) decreases the insemination index by 16%, 3) reduced service period of 28 days, 4) increased milk yield by 10%.

2-Methyl-5-androst-16-EN-3-one formula

< / BR>
as olfactory stimulator reproductive functions of female pigs and cows.

 

Same patents:

The invention relates to a method for producing D-östra-1,3,5(10)-triene-3-ol-17-she (estrone)

The invention relates to new steroid, namely steroid with a 17-spermatocelectomy group having the General formula I, where R1is O, (H, H), (H, or), or NOR, and R is selected from H, (1-6C) alkyl and (1-6C) acyl; R2is H, (1-6C)akilam arbitrarily substituted with halogen, (2-6C)alkenyl arbitrarily substituted with halogen, (2-6C)quinil arbitrarily substituted with halogen, or halogen; R2is H; or R'2together with R2is (1-6C)alkylidene group or (2-6C)allenylidene group; or R'2together with R3are bond; R3is N, if R'2is not a bond; R4is (1-6C)alkyl; one of R5and R6is hydrogen and the other is hydrogen or (1-6C) alkyl; X is (CH2)nor (CnH2n-2), where n is 2 or 3, which is arbitrarily substituted with hydroxyl, halogen, (1-6C)alkyl, (1-6C)acyl, (7-9C)phenylalkyl, phenyl group which may be substituted (1-6C)alkyl, (1-6C)alkoxyl, hydroxyl or halogen; Y is O or (H, HE) and dashed lines show a random link, and at least one of the links 4-5, 5-10 and 9-10 is a double bond

The invention relates to a method for producing intermediate products in the synthesis of steroids with progestogenic activity, namely: Catala steroid derivative of the General formula I

< / BR>
where R1is CH3or C2C5; R2is HE; R3is N, CH3or CH2CN, or R2and R3together are O; R4is (2-5C) alkylene consists in the fact that the compound of formula II

< / BR>
where R1and R2and R3have the previously given meanings, is treated in the presence of artefiera formula III

< / BR>
where R4is (2-5C) alkylene, or orthoevra formula IV

< / BR>
where R4has previously specified value, or a mixture of the alcohol corresponding to the General formula HOR4OH, where R4has the previously given significance

-lactone 3(7-acetylthio-17-hydroxy-3 - oxoandrosta-4-en-17-yl)propionic acid" target="_blank">

The invention relates to pharmaceutical chemistry, and in particular to an improved method for producing a potassium-sparing diuretic such as spironolactone (verospiron, aldactone) of the available raw materials - Starinov of plant and animal origin

The invention relates to a method of isomerization Aquilina or its derivative in the Delta (8,9)-degidro estrone [Delta (8,9)DHE, R1- H, alkyl, acyl or silyl (alkyl)3; R2- H1and R3- OH, O-alkyl or O-silyl (alkyl)3or R2and R3together = O, or R2and R3together acetaline or cycloacetal group, which is characterized by the fact that equilin or its derivative is treated with a lithium salt of Ethylenediamine or Amida lithium in dimethyl sulfoxide

Androstane // 2160740
The invention relates to new androstenone steroids of formula I

< / BR>
where P1OKSO,-(-)hydroxy,-(-)-C1-4-alkoxy or-(-)benzyloxy; P2- C1-4-alkyl, hydroxy-C1-4-alkyl; P3missing or C1-4-alkyl; P4is hydrogen, oxo or hydroxy; P5- one or two hydrogen atoms, methyl or methylene; P6- hydrogen, which are ligand Poluchenie products, communicating with neuroepithelial receptor

Steroid compound // 2160279
The invention relates to extrenely steroids that are associated with neuroepithelial cells in the vomeronasal organ of the human body

The invention relates to 17-deformation-estratriene, to a method for their production and to their use for pharmaceutical products (medicines)

The invention relates to medicine, in particular to urology and andrology

The invention relates to medicine, in particular to andrology and urology

The invention relates to medicine, in particular to andrology and urology
The invention relates to medicine

Androstane // 2160740
The invention relates to new androstenone steroids of formula I

< / BR>
where P1OKSO,-(-)hydroxy,-(-)-C1-4-alkoxy or-(-)benzyloxy; P2- C1-4-alkyl, hydroxy-C1-4-alkyl; P3missing or C1-4-alkyl; P4is hydrogen, oxo or hydroxy; P5- one or two hydrogen atoms, methyl or methylene; P6- hydrogen, which are ligand Poluchenie products, communicating with neuroepithelial receptor

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition as a capsule for oral administration that comprises testosterone undecanoate as an active component dissolved in pharmaceutically acceptable liquid carrier wherein liquid carrier involves at least 50 wt.-% of castor oil. Using castor oil as a liquid carrier in combination with testosterone undecanoate as androgen provides preparing a solution that can contain about 200-250 mg of testosterone undecanoate/ml that represents the new achievement for testosterone solution for oral administration. Solution can contain lipophilic surface-active substance, such as lauryl glycol also. The composition shows good absorption in human body and elicits higher activity as compared with the known composition of undecanoate.

EFFECT: improved and valuable properties of composition.

7 cl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves administering selective modulator of steroid sex hormones being in particular compounds of general formula(I) and some quantity of steroid sex hormones precursor selected from a group composed from dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-en-3β,17β-diol and compounds in vivo transformable into one of cited precursors. Bisphosphonates combined with selective estrogen receptor modulators and/or steroid sex hormones precursor are additionally introduced for medically treating and/or inhibiting osteoporosis progress.

EFFECT: enhanced effectiveness of treatment; excluded adverse side effects.

41 cl, 13 dwg, 4 tbl

FIELD: medicine.

SUBSTANCE: a patient with systemic lupus erythematosus (SLE) should be prescribed to apply efficient quantity of pharmaceutically active form of dehydroepiandrosterone (DHEA) and then, after prescription it is necessary to detect the values for disease activity and total symptoms of the process that characterizes SLE-patient's state, such as: index of SLE activity (IASLE), degree of SLE activity (DSLE), patient's visual analog scale (VAS) and coefficient of Krupp's severity degree (CSDK) to determine the difference between these above-mentioned values obtained before treatment and those taken during therapy, moreover, the decrease of three out of these four values or either the decrease of stabilization or the increase being not higher than by 5% in the fourth value shows that patients reacts to the intake of DHEA.

EFFECT: higher efficiency of therapy.

13 cl, 1 dwg, 8 tbl

FIELD: organic chemistry, steroids, medicine, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to an agent exhibiting structure 7β-hydroxyepiandrosterone or 7β-dehydroepiandrosterone, or their pharmaceutically acceptable esters of the structural formula (I) used for protection of neurons against their damages. Compounds elicit high effectiveness and bioavailability.

EFFECT: valuable medicinal properties of compounds.

15 cl, 3 dwg, 3 tbl, 22 ex

FIELD: medicine.

SUBSTANCE: disclosed is application of 7-hydroxyepiandrosteron as active agent for protection from acute or chronic neuron damage caused by hypoxia, ischemia, stroke, brain trauma, Alzheimer's disease, Parkinson's disease, or spinal cord damage. 7-Hydroxyepiandrosteron increases number of pyramidal cell survivor after ischemia or hypoxia.

EFFECT: new agent with neuroprotective activity.

6 cl, 1 dwg, 2 tbl, 8 ex

Up!